Syngene May Be Listed In The Stock Exchange This Year

Biocon CMD Kiran Mazumdar Shaw

Syngene Will Be Listed After Ensuring Its Continuous Growth

Kiran Mazumdar Shaw, the popular CMD  of Biocon
Kiran Mazumdar Shaw, the popular CMD of Biocon | Source

your vote please

Will Biocon succeed in producing oral insulin?

See results without voting

Oral Insulin Would Have Been A Revolution

Oral Insulin Would Have Been A Revolution

Syngene is the research services arm of the famous Indian pharmaceutical company Biocon Ltd. Biocon is headed by Kiran Mazumdar Shaw, the lady who is famous for her bold corporate decisions. At one point of time, Biocon came very close to achieving the feat of inventing oral insulin. But subsequently the effort failed. Had it succeeded, it would have been a revolution in the pharmaceutical world. Diabetic patients, who inject insulin into their bodies, would have benefitted a lot as their pains would have disappeared with the oral insulin. Now Biocon is planning to list its research services wing Syngene in Indian stock markets during the course of the current year. This was disclosed by Kiran Mazumdar Shaw, CMD of Biocon.

Syngene Will Be Listed After Ensuring Its Continuous Growth

What is holding Biocon from listing Syngene in the bourses? Well, the CMD wants to ensure a 20% growth from quarter to quarter continuously for six quarters and then list the company in the stock markets. For the second quarter of the current financial year ending 30.09.11, Syngene had achieved a growth of 19% in revenue to Rs.93 crore over the previous quarter.

Ongoing International Collaboration

Syngene has ongoing collaboration agreements with sixty biotech and pharmaceutical companies at the international level. Syngene is targeting on new areas of discovery services in connection with biology, chemistry and biologics. Peter Bains is the Director of Syngene International. The company’s strong financial position is further strengthened by its operational performance. Syngene is striving hard to offer broader, stronger and value added services to its international clients through investing in its range of capabilities.

Strengthening R&D Wing

Dr Abhijit Barve has been appointed as the Chief Operating Officer (COO) of Research & Development division of Biocon. Before this appointment, he was serving as the Chief Operating Officer of Clinigene. Dr Abhijit Barve has a wide experience in clinical research and operations. Realising that Biocon’s R&D efforts increasingly focus into clinical products, Kiran Mazumdar Shaw has sensibly roped in Dr Abhijit Barve into this key position to galvanize the division into more efficient one. As Biocon’s R&D is poised to take off to yet another higher level, this appointment will strengthen the system and repose confidence on the company in the minds of its clients.


No comments yet.

    Sign in or sign up and post using a HubPages Network account.

    0 of 8192 characters used
    Post Comment

    No HTML is allowed in comments, but URLs will be hyperlinked. Comments are not for promoting your articles or other sites.

    Click to Rate This Article